B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+25.03%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.13B
AUM Growth
-$243M
(-7.2%)
Cap. Flow
-$918M
Cap. Flow
% of AUM
-29.36%
Top 10 Holdings %
Top 10 Hldgs %
37.92%
Holding
89
New
20
Increased
16
Reduced
29
Closed
16
Avg Time Held
1
year
Top 10 Avg Time Held
0.7
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$55.4M |
| 2 |
Kodiak Sciences
KOD
|
+$42.4M |
| 3 |
BrightSpring Health Services
BTSG
|
+$40.1M |
| 4 |
Celldex Therapeutics
CLDX
|
+$33.4M |
| 5 |
Illumina
ILMN
|
+$31.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xenon Pharmaceuticals
XENE
|
+$74.8M |
| 2 |
Krystal Biotech
KRYS
|
+$67M |
| 3 |
CG Oncology
CGON
|
+$58.5M |
| 4 |
Apogee Therapeutics
APGE
|
+$54.4M |
| 5 |
Danaher
DHR
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.49% |
| 2 | Miscellaneous | 16.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Zura Bio
ZURA
$428M
| $16.7M | 0.53% |
3,180,389
+707,583
| +29% | +$2.8M |
2024 Q3
5 quarters
|
|
52
Compass Therapeutics
CMPX
$150M
| $15M | 0.48% |
+2,786,778
| New | +$12.9M |
2025 Q4
0 quarters
|
|
53
Monte Rosa Therapeutics
GLUE
$852M
| $14.9M | 0.48% |
+948,316
| New | +$12.8M |
2025 Q4
0 quarters
|
|
54
Harrow
HROW
$1.03B
| $14.5M | 0.46% |
295,291
-47,100
| -14% | -$1.98M |
2023 Q1
11 quarters
|
|
55
X4 Pharmaceuticals
XFOR
$244M
| $13.5M | 0.43% |
+3,368,904
| New | +$12.2M |
2025 Q4
0 quarters
|
|
56
Repligen
RGEN
$11.4B
| $13.4M | 0.43% |
81,790
-113,866
| -58% | -$17.8M |
2023 Q2
10 quarters
|
|
57
Icon
ICLR
$13B
| $13.4M | 0.43% |
+73,370
| New | +$13.1M |
2025 Q4
0 quarters
|
|
58
Kiniksa Pharmaceuticals
KNSA
$6.17B
| $12.9M | 0.41% |
313,823
-329,357
| -51% | -$13.2M |
2024 Q1
7 quarters
|
|
59
GRAIL Inc
GRAL
$6.2B
| $12.2M | 0.39% |
+142,755
| New | +$12.3M |
2025 Q4
0 quarters
|
|
60
Surrozen
SRZN
$278M
| $10.6M | 0.34% |
470,000
+330,000
| +236% | +$5.34M |
2025 Q2
2 quarters
|
|
61
Relmada Therapeutics
RLMD
$349M
| $7.64M | 0.24% |
+1,582,257
| New | +$5.3M |
2025 Q4
0 quarters
|
|
62
Xencor
XNCR
$1.77B
| $7.03M | 0.22% |
459,166
-787,114
| -63% | -$11.8M |
2024 Q3
5 quarters
|
|
63
Castle Biosciences
CSTL
$1.01B
| $6.89M | 0.22% |
177,183
-645,552
| -78% | -$20.8M |
2025 Q1
3 quarters
|
|
64
Adaptive Biotechnologies
ADPT
$4.07B
| $5.07M | 0.16% |
311,991
-424,023
| -58% | -$6.92M |
2025 Q1
3 quarters
|
|
65
BillionToOne Inc
BLLN
$4.6B
| $4.09M | 0.13% |
+50,000
| New | +$5.07M |
2025 Q4
0 quarters
|
|
66
Oruka Therapeutics
ORKA
$5.08B
| $2.57M | 0.08% |
84,795
-1,297,555
| -94% | -$36.2M |
2024 Q3
5 quarters
|
|
67
Karyopharm Therapeutics
KPTI
$7.89M
| $2.23M | 0.07% |
+303,370
| New | +$1.86M |
2025 Q4
0 quarters
|
|
68
Pulmonx
LUNG
$76.4M
| $1.66M | 0.05% |
752,541
| – | – |
2022 Q4
12 quarters
|
|
69
DELISTED
Akero Therapeutics
AKRO
| – | – |
-475,400
| Closed | -$22.6M | – |
|
70
Amylyx Pharmaceuticals
AMLX
$3.42B
| – | – |
-612,841
| Closed | -$8.33M | – |
|
71
Alphatec Holdings
ATEC
$1.6B
| – | – |
-1,514,604
| Closed | -$22M | – |
|
72
DELISTED
Day One Biopharmaceuticals
DAWN
| – | – |
-2,181,598
| Closed | -$15.4M | – |
|
73
Encompass Health
EHC
$12.5B
| – | – |
-113,335
| Closed | -$14.4M | – |
|
74
DELISTED
Exact Sciences
EXAS
| – | – |
-414,600
| Closed | -$22.7M | – |
|
75
Globus Medical
GMED
$10.2B
| – | – |
-498,000
| Closed | -$28.5M | – |
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q4 2025 Portfolio in Review
As of Q4 2025, Braidwell held 89 positions worth $3.13B, down 7.2% from $3.37B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Braidwell withdrew a net $918M in Q4 2025, closing 16 positions and reducing 29 holdings. Its most notable exit was Globus Medical, an estimated $28.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 73% a quarter earlier, followed by Miscellaneous.
Against the trend, Braidwell opened a new position in Centessa Pharmaceuticals worth $54.7M.
- Braidwell's largest Q4 2025 buy was Centessa Pharmaceuticals: 2,188,320 shares worth $54.7M.
- Braidwell added most to Celldex Therapeutics in Q4 2025, an estimated $33.4M increase.
- Braidwell's biggest Q4 2025 reduction was Xenon Pharmaceuticals, cutting an estimated $74.8M.
- Braidwell fully exited Globus Medical in Q4 2025, selling an estimated $28.5M.
- Braidwell's ten largest holdings make up 38% of its $3.13B portfolio in Q4 2025.
- Braidwell opened 20 new positions and closed 16 in Q4 2025.
- Braidwell's portfolio value fell 7.2% quarter-over-quarter to $3.13B.
Based on Braidwell's 13F filing for Q4 2025, filed 17 Feb 2026.